|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In HNSCC patients, coexpression of GLI1 and SMO in primary tumors correlated with metastasis.
|
31408253 |
2020 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we assessed the ability of five popular classifiers (J48, AdaboostM1, SMO, Bayes Net, and Naïve Bayes) to identify individuals with diabetes based on nine non-invasive and easily obtained clinical features, including age, gender, body mass index (BMI), hypertension, history of cardiovascular disease or stroke, family history of diabetes, physical activity, work stress, and salty food preference.
|
30866905 |
2019 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed the ability of five popular classifiers (J48, AdaboostM1, SMO, Bayes Net, and Naïve Bayes) to identify individuals with diabetes based on nine non-invasive and easily obtained clinical features, including age, gender, body mass index (BMI), hypertension, history of cardiovascular disease or stroke, family history of diabetes, physical activity, work stress, and salty food preference.
|
30866905 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we assessed the ability of five popular classifiers (J48, AdaboostM1, SMO, Bayes Net, and Naïve Bayes) to identify individuals with diabetes based on nine non-invasive and easily obtained clinical features, including age, gender, body mass index (BMI), hypertension, history of cardiovascular disease or stroke, family history of diabetes, physical activity, work stress, and salty food preference.
|
30866905 |
2019 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we assessed the ability of five popular classifiers (J48, AdaboostM1, SMO, Bayes Net, and Naïve Bayes) to identify individuals with diabetes based on nine non-invasive and easily obtained clinical features, including age, gender, body mass index (BMI), hypertension, history of cardiovascular disease or stroke, family history of diabetes, physical activity, work stress, and salty food preference.
|
30866905 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
7-KC downregulated the SHh protein in LMSCs but did not change the expression of SMO.
|
31117185 |
2019 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, the SMO inhibitor cyclopamine enhances the cytotoxic effects of bortezomib in MM cell lines.
|
30644322 |
2019 |
|
Radicular Cyst
|
0.010 |
Biomarker
|
disease |
BEFREE |
Current study investigated whether single-nucleotide polymorphisms in the hedgehog pathway genes PTCH1, GLI1, SMO, and VDR contribute to susceptibility to odontogenic cystic lesions, odontogenic keratocysts, or inflammatory radicular cysts.
|
30334169 |
2019 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we assessed the ability of five popular classifiers (J48, AdaboostM1, SMO, Bayes Net, and Naïve Bayes) to identify individuals with diabetes based on nine non-invasive and easily obtained clinical features, including age, gender, body mass index (BMI), hypertension, history of cardiovascular disease or stroke, family history of diabetes, physical activity, work stress, and salty food preference.
|
30866905 |
2019 |
|
Myxofibroma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hh pathway inhibition with SMO antagonists may represent a target to study for treating a subset of plexiform fibromyxomas.
|
31362756 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Pancreatic cancer is a highly malignant cancer associated with high expression levels of sonic hedgehog signaling molecule (Shh), patched 1 (Ptch1), smoothened frizzled class receptor (Smo) and glioma-associated oncogene family zinc finger 1 (Gli1) in the hedgehog (Hh) signaling pathway.
|
31611949 |
2019 |
|
Irido-corneal dysgenesis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here we reported the first identification of compound heterozygous mutations (c.G338A; p.R113Q and c.C1619T; p.A540V) in the SMO gene in a patient with both anterior segment dysgenesis (congenital corneal opacity, cataract) and morning glory syndrome, using trio-based whole exome sequencing.
|
31301482 |
2019 |
|
Malignant Head and Neck Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although it needs to be confirmed in larger cohorts, our results suggest that targeting SMO might be a potentially therapeutic option in patients with head and neck cancer.
|
30861166 |
2019 |
|
Congenital corneal opacity
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here we reported the first identification of compound heterozygous mutations (c.G338A; p.R113Q and c.C1619T; p.A540V) in the SMO gene in a patient with both anterior segment dysgenesis (congenital corneal opacity, cataract) and morning glory syndrome, using trio-based whole exome sequencing.
|
31301482 |
2019 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Pancreatic cancer is a highly malignant cancer associated with high expression levels of sonic hedgehog signaling molecule (Shh), patched 1 (Ptch1), smoothened frizzled class receptor (Smo) and glioma-associated oncogene family zinc finger 1 (Gli1) in the hedgehog (Hh) signaling pathway.
|
31611949 |
2019 |
|
Unicystic ameloblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among the BRAF wild-type cases, 1 UAM showed a missense SMO mutation (p.L412F), whereas 2 NRAS (p.Q61R), 2 HRAS (p.Q61R), and 2 FGFR2 (p.C383R) activating mutations were identified in AM.
|
30216733 |
2019 |
|
Morning glory syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here we reported the first identification of compound heterozygous mutations (c.G338A; p.R113Q and c.C1619T; p.A540V) in the SMO gene in a patient with both anterior segment dysgenesis (congenital corneal opacity, cataract) and morning glory syndrome, using trio-based whole exome sequencing.
|
31301482 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hedgehog pathway proteins SMO and GLI expression as prognostic markers in head and neck squamous cell carcinoma.
|
30861166 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
|
31363010 |
2019 |
|
Solid/Multicystic Ameloblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among the BRAF wild-type cases, 1 UAM showed a missense SMO mutation (p.L412F), whereas 2 NRAS (p.Q61R), 2 HRAS (p.Q61R), and 2 FGFR2 (p.C383R) activating mutations were identified in AM.
|
30216733 |
2019 |
|
Head and Neck Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although it needs to be confirmed in larger cohorts, our results suggest that targeting SMO might be a potentially therapeutic option in patients with head and neck cancer.
|
30861166 |
2019 |
|
Halitosis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
This work paves the way for a new class of cosensitization routes to overcome critical shortcomings of SMO-based chemical sensors, thus providing a potential platform for diagnosis of halitosis.
|
29762012 |
2018 |
|
Histiocytoid hemangioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Deleterious variants TP53 c.707T>C (p.Tyr236Cys), FLT3 c.1995C>T (p.Met665Ile), and SMO c.1919C>T (p.Thr640Ile) were detected in EH, while AS revealed deleterious variant PTPN11 c.226G>A (p.Glu76Lys).
|
29206716 |
2018 |
|
Epithelioid hemangioendothelioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Deleterious variants TP53 c.707T>C (p.Tyr236Cys), FLT3 c.1995C>T (p.Met665Ile), and SMO c.1919C>T (p.Thr640Ile) were detected in EH, while AS revealed deleterious variant PTPN11 c.226G>A (p.Glu76Lys).
|
29206716 |
2018 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, we demonstrate that MEG3 inhibits Hh-mediated EMT process in liver fibrosis via SMO protein and miR-212.
|
30282972 |
2018 |